ArticleOncotarget2017
Aspirin exerts high anti-cancer activity in
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- New Oxicam Derivatives-Studies of Membrane Interactions, Cytotoxicity, Cyclooxygenase Inhibition and Molecular Docking.Membranes · 2026Article
- Aspirin alters molecular crosstalk between prostaglandin, apoptosis, and invasion pathways in colorectal cancer.BMC cancer · 2026Article
- Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.Scientific reports · 2026Article
- Artificial intelligence driven multi-omics framework identifies COL6A3 as a diagnostic biomarker and a putative gene target modulated by Embelin in Colorectal cancer.Frontiers in oncology · 2026Article
- Genomic and cellular responses to aspirin in colonic organoids from African- and European-Americans.Physiological genomics · 2025Article
- Sustainable Nanomedicine: Enhancement of Asplatin's Cytotoxicity In Vitro and In Vivo Using Green-Synthesized Zinc Oxide Nanoparticles Formed via Microwave-Assisted and Gambogic Acid-Mediated Processes.Molecules (Basel, Switzerland) · 2024Article
- Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence.Cureus · 2024Review
- Genomic and epigenomic responses to aspirin in human colonic organoids.Physiological genomics · 2023Article
- Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Colorectal cancer chemoprevention: is aspirin still in the game?Cancer biology & therapy · 2022Review
- Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.Cellular and molecular life sciences : CMLS · 2022Review
- Comparison of Absolute Expression and Turnover Number of COX-1 and COX-2 in Human and Rodent Cells and Tissues.Journal of inflammation research · 2022Article
- Association ofOncoimmunology · 2021Article
- Deactivation of Glutaminolysis SensitizesCancers · 2020Article
- Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity.Therapeutic advances in medical oncology · 2020Article
- Two Isoforms of the Guanine Nucleotide Exchange Factor, Daple/CCDC88C Cooperate as Tumor Suppressors.Scientific reports · 2019Article
- Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.British journal of cancer · 2019Review
- Silencing theYonsei medical journal · 2019Article
- Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology.Annual review of pathology · 2019Review
- Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.Medical sciences (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
Mancang GuDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Reiko NishiharaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Yang ChenDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Wanwan LiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Yan ShiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Yohei MasugiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Tsuyoshi HamadaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Keisuke KosumiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Li LiuDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Annacarolina da SilvaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tyler TwomblyDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Chunxia DuDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Hideo KohDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Wenbin LiDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Adam J BassDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
David A DrewClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Charles S Fuchs *Yale Cancer Center, New Haven, CT, USA.
Zhi Rong Qian *Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Shuji Ogino *Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Harvard University · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USMassachusetts General Hospital · USYale Cancer Center · USZhejiang Chinese Medical University · CN
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MPilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1991 to 2026
$35.3MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MHarvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5MInflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5MAccelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0MDietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4MImpact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9MMentored Patient-Oriented Research in Digestive DiseasesK24DK098311 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2013 to 2017
$930kLifestyle, genetics and colonoscopy for colorectal cancer preventionK07CA190673 · NCI · DANA-FARBER CANCER INST · PI NISHIHARA, REIKO · 2014 to 2018
$609kNCATS NIH HHS KL2 TR001100NCATS NIH HHS UL1 TR001102NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA190673NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA169141NCI NIH HHS R35 CA197735NIDDK NIH HHS K24 DK098311NIDDK NIH HHS P30 DK043351
Abstract
Evidence suggests that nonsteroidal anti-inflammatory drug aspirin (acetylsalicylic acid) may improve patient survival in
Indexed as
anti-tumor effectcolorectal cancerisogenic cell modelNSAIDPI3K
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.